Then, in phase IIB clinical trials, about twenty cases with mutated FLT3 with reverted AML or highly aggressive myeloblastic conditions were investigated versus individual Midostaurin therapy [58]. This evidence concerns the gene FLT3 and acute myeloid leukemia.